BriaCell Therapeutics Corporation

Quick facts

Phase 3 pipeline

• SV-BR-1-GM · Oncology
  SV-BR-1-GM is an autologous breast cancer immunotherapy that uses patient-derived dendritic cells loaded with breast cancer-associated antigens to stimulate anti-tumor immune responses.

Phase 1 pipeline

• BC1 cell line
• Interferon Inoculation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BriaCell Therapeutics Corporation portfolio CI brief
• BriaCell Therapeutics Corporation pipeline updates RSS